A preclinical (188) Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49
Page 1 of 1
A preclinical (188) Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49
Jon Moulton Mon Nov 29, 2010 9:55 am
Liu G, Dou S, Baker S, Akalin A, Cheng D, Chen L, Rusckowski M, Hnatowich DJ. A preclinical (188) Re tumor therapeutic investigation using MORF/cMORF pretargeting and an antiTAG-72 antibody CC49. Cancer Biol Ther. 2010 Nov 22;10(8):767-74.
Jon Moulton- Posts : 5721
Join date : 2010-03-12
Age : 61
Location : Philomath, Oregon, USA -
Similar topics» Human islet cell MORF/cMORF pretargeting in a xenogeneic murine transplant model
» The ratio of maximum percent tumor accumulations of the pretargeting agent and the radiolabeled effector is independent of tumor size
» Affinity Enhancement Pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF
» Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted
» Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody
» The ratio of maximum percent tumor accumulations of the pretargeting agent and the radiolabeled effector is independent of tumor size
» Affinity Enhancement Pretargeting: synthesis and testing of a 99mTc-labeled bivalent MORF
» Adding a clearing agent to pretargeting does not lower the tumor accumulation of the effector as predicted
» Pretargeting vs. direct targeting of human betalox5 islet cells subcutaneously implanted in mice using an anti-human islet cell antibody
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum